What You Need to Know to Avoid Costly Delays in Your API Scale-Up

Traditionally, the development of a small-scale synthesis for an active pharmaceutical ingredient (API) and its scale-up to meet the materials demand for clinical trial phases is a sequential activity that passes through multiple sets of hands. Even if the synthesis used at a small scale is the same one used at a large scale, the developer must be prepared to encounter and react to any changes to the API’s quality attributes, such as by-product profile and physical form.

Learn why a company must be aware of any potential conditions that could occur at a small-scale that could create major issues during commercial scale-up.

Please complete this short form to download this whitepaper.

Max Character Limit 45

Max Character Limit 45

Max Character Limit 460 - error sit voluptatem accusantium doloremque laudantium, totam rem aperiam, eaque ipsa quae ab illo inventore veritatis et quasi architecto sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam, eaque ipsa quae ab illo inventore veritatis et quasi architecto.